PATENT CLAIM ANALYSIS

Application Number: 15773084
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "017600"]

Abstract:
This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need thereof, comprising administering e.g., rapastinel and an atypical antipsychotic.

Claim (Index 12):
The method of  claim 1 , wherein the NMDA modulator and the atypical antipsychotic are administered sequentially.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.31429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15320155', '14770331', '15547776', '12829526', '15341275']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7639421990985638
- 35 USC 102 Novelty (BERT): 0.5093355604574463
- Combined Prediction Score: 0.738481535234452
- Mean Citation Score: 213.488412
- Max Citation Score: 227.16086
- Similarity Product: 137.2212655699301

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test